Utilizing a TLR5-adjuvanted cytomegalovirus as a lentiviral vaccine in the nonhuman primate model for AIDS

Jesse D. Deere, W. L William Chang, Luis D. Castillo, Kim A. Schmidt, Hung T. Kieu, Nicholas Renzette, Timothy Kowalik, Stephen W Barthold, Barbara Shacklett, Peter A Barry, Ellen E. Sparger

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Despite tremendous progress in our understanding of human immunodeficiency virus (HIV) natural history and advances in HIV treatment, there is neither an approved vaccine nor a cure for infection. Here, we describe the development and characterization of a novel replicating vaccine vector utilizing Cytomegalovirus (CMV) and a TLR5 adjuvant. After partial truncation of the central, immunodominant hypervariable domain, flagellin (fliC) from Salmonella was cloned downstream of a codon optimized gag gene from simian immunodeficiency virus (SIV) and transiently expressed in telomerized rhesus fibroblast (TeloRF) cells in culture. Lysates generated from these transfected cells induced the tumor necrosis factor alpha (TNF-α), in a mouse macrophage cell line, in a TLR5-dependent manner. The Gag/ FliC expression construct was cloned into a bacterial artificial chromosome encoding the rhesus CMV (RhCMV) genome, and infectious RhCMV was generated following transfection of TeloRF cells. This virus stably expressed an SIV Gag/FliC fusion protein through four serial passages. Lysates generated from infected cells induced TNF-α in a TLR5-dependent manner. Western blot analysis of infected cell lysates verified expression of a Gag/FliC fusion protein using a SIV p27 capsid monoclonal antibody. Lastly, rhesus macaques inoculated with this novel RhCMV virus demonstrated increased inflammatory responses at the site of inoculation seven days post-infection when compared to the parental RhCMV. These results demonstrate that an artificially constructed replicating RhCMV expressing an SIV Gag/FliC fusion protein is capable of activating TLR5 in a macrophage cell line in vitro and induction of an altered inflammatory response in vivo. Ongoing animals studies are aimed at determining vaccine efficacy, including subsequent challenge with pathogenic SIV.

Original languageEnglish (US)
Article numbere0155629
JournalPLoS One
Volume11
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Simian immunodeficiency virus
Cytomegalovirus
Simian Immunodeficiency Virus
Viruses
Primates
Acquired Immunodeficiency Syndrome
Vaccines
animal models
vaccines
Human immunodeficiency virus
tumor necrosis factor-alpha
fibroblasts
macrophages
Tumor Necrosis Factor-alpha
Fibroblasts
inflammation
Macrophages
cell lines
HIV
gag Genes

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Deere, J. D., Chang, W. L. W., Castillo, L. D., Schmidt, K. A., Kieu, H. T., Renzette, N., ... Sparger, E. E. (2016). Utilizing a TLR5-adjuvanted cytomegalovirus as a lentiviral vaccine in the nonhuman primate model for AIDS. PLoS One, 11(5), [e0155629]. https://doi.org/10.1371/journal.pone.0155629

Utilizing a TLR5-adjuvanted cytomegalovirus as a lentiviral vaccine in the nonhuman primate model for AIDS. / Deere, Jesse D.; Chang, W. L William; Castillo, Luis D.; Schmidt, Kim A.; Kieu, Hung T.; Renzette, Nicholas; Kowalik, Timothy; Barthold, Stephen W; Shacklett, Barbara; Barry, Peter A; Sparger, Ellen E.

In: PLoS One, Vol. 11, No. 5, e0155629, 01.05.2016.

Research output: Contribution to journalArticle

Deere, JD, Chang, WLW, Castillo, LD, Schmidt, KA, Kieu, HT, Renzette, N, Kowalik, T, Barthold, SW, Shacklett, B, Barry, PA & Sparger, EE 2016, 'Utilizing a TLR5-adjuvanted cytomegalovirus as a lentiviral vaccine in the nonhuman primate model for AIDS', PLoS One, vol. 11, no. 5, e0155629. https://doi.org/10.1371/journal.pone.0155629
Deere, Jesse D. ; Chang, W. L William ; Castillo, Luis D. ; Schmidt, Kim A. ; Kieu, Hung T. ; Renzette, Nicholas ; Kowalik, Timothy ; Barthold, Stephen W ; Shacklett, Barbara ; Barry, Peter A ; Sparger, Ellen E. / Utilizing a TLR5-adjuvanted cytomegalovirus as a lentiviral vaccine in the nonhuman primate model for AIDS. In: PLoS One. 2016 ; Vol. 11, No. 5.
@article{9a2817b3808a403f8bf24e88a92466a4,
title = "Utilizing a TLR5-adjuvanted cytomegalovirus as a lentiviral vaccine in the nonhuman primate model for AIDS",
abstract = "Despite tremendous progress in our understanding of human immunodeficiency virus (HIV) natural history and advances in HIV treatment, there is neither an approved vaccine nor a cure for infection. Here, we describe the development and characterization of a novel replicating vaccine vector utilizing Cytomegalovirus (CMV) and a TLR5 adjuvant. After partial truncation of the central, immunodominant hypervariable domain, flagellin (fliC) from Salmonella was cloned downstream of a codon optimized gag gene from simian immunodeficiency virus (SIV) and transiently expressed in telomerized rhesus fibroblast (TeloRF) cells in culture. Lysates generated from these transfected cells induced the tumor necrosis factor alpha (TNF-α), in a mouse macrophage cell line, in a TLR5-dependent manner. The Gag/ FliC expression construct was cloned into a bacterial artificial chromosome encoding the rhesus CMV (RhCMV) genome, and infectious RhCMV was generated following transfection of TeloRF cells. This virus stably expressed an SIV Gag/FliC fusion protein through four serial passages. Lysates generated from infected cells induced TNF-α in a TLR5-dependent manner. Western blot analysis of infected cell lysates verified expression of a Gag/FliC fusion protein using a SIV p27 capsid monoclonal antibody. Lastly, rhesus macaques inoculated with this novel RhCMV virus demonstrated increased inflammatory responses at the site of inoculation seven days post-infection when compared to the parental RhCMV. These results demonstrate that an artificially constructed replicating RhCMV expressing an SIV Gag/FliC fusion protein is capable of activating TLR5 in a macrophage cell line in vitro and induction of an altered inflammatory response in vivo. Ongoing animals studies are aimed at determining vaccine efficacy, including subsequent challenge with pathogenic SIV.",
author = "Deere, {Jesse D.} and Chang, {W. L William} and Castillo, {Luis D.} and Schmidt, {Kim A.} and Kieu, {Hung T.} and Nicholas Renzette and Timothy Kowalik and Barthold, {Stephen W} and Barbara Shacklett and Barry, {Peter A} and Sparger, {Ellen E.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1371/journal.pone.0155629",
language = "English (US)",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Utilizing a TLR5-adjuvanted cytomegalovirus as a lentiviral vaccine in the nonhuman primate model for AIDS

AU - Deere, Jesse D.

AU - Chang, W. L William

AU - Castillo, Luis D.

AU - Schmidt, Kim A.

AU - Kieu, Hung T.

AU - Renzette, Nicholas

AU - Kowalik, Timothy

AU - Barthold, Stephen W

AU - Shacklett, Barbara

AU - Barry, Peter A

AU - Sparger, Ellen E.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Despite tremendous progress in our understanding of human immunodeficiency virus (HIV) natural history and advances in HIV treatment, there is neither an approved vaccine nor a cure for infection. Here, we describe the development and characterization of a novel replicating vaccine vector utilizing Cytomegalovirus (CMV) and a TLR5 adjuvant. After partial truncation of the central, immunodominant hypervariable domain, flagellin (fliC) from Salmonella was cloned downstream of a codon optimized gag gene from simian immunodeficiency virus (SIV) and transiently expressed in telomerized rhesus fibroblast (TeloRF) cells in culture. Lysates generated from these transfected cells induced the tumor necrosis factor alpha (TNF-α), in a mouse macrophage cell line, in a TLR5-dependent manner. The Gag/ FliC expression construct was cloned into a bacterial artificial chromosome encoding the rhesus CMV (RhCMV) genome, and infectious RhCMV was generated following transfection of TeloRF cells. This virus stably expressed an SIV Gag/FliC fusion protein through four serial passages. Lysates generated from infected cells induced TNF-α in a TLR5-dependent manner. Western blot analysis of infected cell lysates verified expression of a Gag/FliC fusion protein using a SIV p27 capsid monoclonal antibody. Lastly, rhesus macaques inoculated with this novel RhCMV virus demonstrated increased inflammatory responses at the site of inoculation seven days post-infection when compared to the parental RhCMV. These results demonstrate that an artificially constructed replicating RhCMV expressing an SIV Gag/FliC fusion protein is capable of activating TLR5 in a macrophage cell line in vitro and induction of an altered inflammatory response in vivo. Ongoing animals studies are aimed at determining vaccine efficacy, including subsequent challenge with pathogenic SIV.

AB - Despite tremendous progress in our understanding of human immunodeficiency virus (HIV) natural history and advances in HIV treatment, there is neither an approved vaccine nor a cure for infection. Here, we describe the development and characterization of a novel replicating vaccine vector utilizing Cytomegalovirus (CMV) and a TLR5 adjuvant. After partial truncation of the central, immunodominant hypervariable domain, flagellin (fliC) from Salmonella was cloned downstream of a codon optimized gag gene from simian immunodeficiency virus (SIV) and transiently expressed in telomerized rhesus fibroblast (TeloRF) cells in culture. Lysates generated from these transfected cells induced the tumor necrosis factor alpha (TNF-α), in a mouse macrophage cell line, in a TLR5-dependent manner. The Gag/ FliC expression construct was cloned into a bacterial artificial chromosome encoding the rhesus CMV (RhCMV) genome, and infectious RhCMV was generated following transfection of TeloRF cells. This virus stably expressed an SIV Gag/FliC fusion protein through four serial passages. Lysates generated from infected cells induced TNF-α in a TLR5-dependent manner. Western blot analysis of infected cell lysates verified expression of a Gag/FliC fusion protein using a SIV p27 capsid monoclonal antibody. Lastly, rhesus macaques inoculated with this novel RhCMV virus demonstrated increased inflammatory responses at the site of inoculation seven days post-infection when compared to the parental RhCMV. These results demonstrate that an artificially constructed replicating RhCMV expressing an SIV Gag/FliC fusion protein is capable of activating TLR5 in a macrophage cell line in vitro and induction of an altered inflammatory response in vivo. Ongoing animals studies are aimed at determining vaccine efficacy, including subsequent challenge with pathogenic SIV.

UR - http://www.scopus.com/inward/record.url?scp=84969850451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969850451&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0155629

DO - 10.1371/journal.pone.0155629

M3 - Article

C2 - 27182601

AN - SCOPUS:84969850451

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e0155629

ER -